Market News AIOpen the app

Mirum Pharmaceuticals' stock is going up today after good news about its drug LIVMARLI.

ResultsRead the original at Benzinga
Good for MIRM

Mirum reported that LIVMARLI met the study's main goal and all 5 additional measures, with better itching and bile-acid results than placebo. Serious events occurred, but none were judged related to treatment and researchers found no new safety concerns, so the trial news favors Mirum.

MIRM · Mirum Pharmaceuticals, Inc.

AI read · Good for MIRM

The AI's read

The results give Mirum stronger evidence that LIVMARLI can ease itching and reduce bile acids in children with rare liver conditions. Serious health problems occurred among treated patients, but researchers did not link them to the drug and found no new safety concerns. The study included 52 people and does not establish approval or sales.

Get alerts for MIRM

Follow Mirum Pharmaceuticals, Inc. (MIRM) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MIRM
Free on the App Store and Google Play, or on the web.